SG11202008508QA - Hepatitis b vaccines and uses of the same - Google Patents

Hepatitis b vaccines and uses of the same

Info

Publication number
SG11202008508QA
SG11202008508QA SG11202008508QA SG11202008508QA SG11202008508QA SG 11202008508Q A SG11202008508Q A SG 11202008508QA SG 11202008508Q A SG11202008508Q A SG 11202008508QA SG 11202008508Q A SG11202008508Q A SG 11202008508QA SG 11202008508Q A SG11202008508Q A SG 11202008508QA
Authority
SG
Singapore
Prior art keywords
vaccines
hepatitis
same
Prior art date
Application number
SG11202008508QA
Other languages
English (en)
Inventor
Douglas E Brough
Cheryl G Bolinger
Ramya Yarlagadda
Vinodhbabu Kurella
Ponraj Prabakaran
Simon Metenou
Kuan-Fu Ding
Original Assignee
Precigen Inc
Pgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precigen Inc, Pgen Therapeutics Inc filed Critical Precigen Inc
Publication of SG11202008508QA publication Critical patent/SG11202008508QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202008508QA 2018-03-06 2019-03-06 Hepatitis b vaccines and uses of the same SG11202008508QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639354P 2018-03-06 2018-03-06
PCT/US2019/020930 WO2019173463A1 (fr) 2018-03-06 2019-03-06 Vaccins contre l'hépatite b et utilisations de ces derniers

Publications (1)

Publication Number Publication Date
SG11202008508QA true SG11202008508QA (en) 2020-10-29

Family

ID=67845806

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008508QA SG11202008508QA (en) 2018-03-06 2019-03-06 Hepatitis b vaccines and uses of the same

Country Status (11)

Country Link
US (2) US11608362B2 (fr)
EP (1) EP3762010A4 (fr)
JP (2) JP2021514666A (fr)
KR (1) KR20200128703A (fr)
CN (1) CN112135622A (fr)
AU (1) AU2019231652A1 (fr)
CA (1) CA3092935A1 (fr)
IL (1) IL277128A (fr)
SG (1) SG11202008508QA (fr)
WO (1) WO2019173463A1 (fr)
ZA (1) ZA202005672B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092935A1 (fr) 2018-03-06 2019-09-12 Precigen, Inc. Vaccins contre l'hepatite b et utilisations de ces derniers
CA3156704A1 (fr) * 2019-10-09 2021-04-15 Edward Fritsch Vaccin a proteines multi-domaines

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
FR2593630B1 (fr) 1986-01-27 1988-03-18 Maurice Francois Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1991014695A1 (fr) 1990-03-22 1991-10-03 The Salk Institute For Biological Studies Compositions et procedes de recepteur resinoides d'insectes
CA2043775A1 (fr) 1990-06-14 1991-12-15 Dat P. Le Dibenzoylalkylcyanohydrazines
CA2096222C (fr) 1990-11-13 1998-12-29 Stephen D. Lupton Genes de fusion selectables et bifonctionnelles
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
EP0804590A1 (fr) 1993-05-21 1997-11-05 Targeted Genetics Corporation Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69435108D1 (de) 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
WO1995016772A1 (fr) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Systeme d'expression du gene d'adenovirus
EP1548118A2 (fr) 1994-06-10 2005-06-29 Genvec, Inc. Système de vecteurs adenoviraux complémentaires et lignées cellulaires correspondantes
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
WO1996027673A1 (fr) 1995-03-03 1996-09-12 Novartis Ag Regulation de l'expression genique dans les plantes par transactivation induite par recepteur en presence d'un ligand chimique
ATE278794T1 (de) 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
EP0910652B1 (fr) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Techniques liees a une utilisation d'hormones visant a moduler l'expression de genes exogenes chez des mammiferes et produits connexes
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
CA2296093A1 (fr) 1997-07-10 1999-01-21 The Salk Institute For Biological Studies Proteines multifonctionnelles hybrides et recepteurs de lepidopterane modifies destines a etre utilises pour reguler l'expression transgenique
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
WO2001030965A2 (fr) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methodes de transfert genique in vivo a l'aide d'un systeme de transposon «sleeping beauty»
CA2404253C (fr) 2000-03-22 2014-05-13 Rohm And Haas Company Nouveau systeme d'expression genetique inducible fonde sur le le recepteur a l'ecdysone
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
AU6616301A (en) 2000-06-22 2002-01-02 Celltech Pharmaceuticals Ltd Modification of hepatitis b core antigen
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US8715959B2 (en) 2001-02-20 2014-05-06 Intrexon Corporation Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
JP4955905B2 (ja) 2001-02-20 2012-06-20 イントレキソン コーポレーション キメラレチノイドｘ受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
US9249207B2 (en) 2001-02-20 2016-02-02 Intrexon Corporation Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
AU2002327380A1 (en) 2001-07-23 2003-03-18 Genvec, Inc. Cells and methods for propagating adenoviral vectors
JP2005503797A (ja) 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
EP1436394A4 (fr) 2001-09-26 2004-12-29 Rheo Gene Holdings Inc Acides nucleiques du recepteur a l'ecdysone de la cicadelle, polypeptides, et utilisation de ceux-ci
CA2459807C (fr) 2001-09-26 2013-09-03 Jianzhong Zhang Acides nucleiques, polypeptides du recepteur de l'ecdysone des aleyrodidae et utilisations ces derniers
WO2003089618A2 (fr) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Systeme de transposons, et procedes d'utilisation
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
ATE503492T1 (de) 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CA2868867A1 (fr) 2005-03-25 2006-09-28 National Research Council Of Canada Procede d'isolation de polypeptides solubles
WO2007073513A2 (fr) 2005-11-10 2007-06-28 Genvec, Inc. Procede de propagation de vecteurs adenoviraux codant pour des produits geniques inhibiteurs
US9388425B2 (en) 2006-10-20 2016-07-12 Trustees Of Boston University Tunable genetic switch for regulating gene expression
US8603950B2 (en) 2007-02-20 2013-12-10 Anaptysbio, Inc. Methods of generating libraries and uses thereof
BRPI0811348B1 (pt) 2007-05-29 2022-02-08 Intrexon Corporation Composto, (n-(1-ter-butil-butil)-n'-(2-etil-3-metóxi benzoil)-hidrazida de ácido (r)-3,5-dimetilbenzóico e composição farmacêutica
GB0710538D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
EP2160461B1 (fr) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Variantes hyperactives de protéine transposase du système de transposon sleeping beauty
CA2715080C (fr) 2007-09-28 2021-09-28 Intrexon Corporation Constructions et bioreacteurs de commutation de gene theapeutique destines a l'expression de molecules biotherapeutiques, et utilisation de ceux-ci
EP2207874B1 (fr) 2007-10-08 2014-12-03 Intrexon Corporation Cellules dendritiques synthétisées et utilisations pour le traitement du cancer
BRPI0920679A2 (pt) 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
JP5897464B2 (ja) * 2009-08-07 2016-03-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Ｈｂｖ感染を治療するための組成物
TWI688395B (zh) 2010-03-23 2020-03-21 英翠克頌公司 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
EP2672991B1 (fr) 2011-02-12 2017-07-19 Globeimmune, Inc. Thérapeutique à base de levure pour infection chronique par l'hépatite b
EP2681327B1 (fr) 2011-03-04 2018-11-21 Intrexon Corporation Vecteurs exprimant une protéine de façon conditionnelle
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
CA2850627C (fr) 2011-10-05 2024-05-21 Genvec, Inc. Vecteurs adenoviraux et procedes d'utilisation
CN107574154A (zh) 2011-10-05 2018-01-12 金维克有限公司 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
IN2014DN03005A (fr) 2011-10-05 2015-05-08 Genvec Inc
WO2015095249A1 (fr) 2013-12-18 2015-06-25 Intrexon Corporation Acides nucléiques d'il-12 monocaténaires, polypeptides d'il-12 monocaténaires, et leurs utilisations
CN106573960B (zh) * 2014-06-02 2021-07-02 Isa制药有限公司 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp)
WO2016020538A1 (fr) * 2014-08-08 2016-02-11 Transgene Sa Traitement en association d'un vaccin contre le hbv et d'un anticorps pour traiter des infections à hbv.
AU2015321603A1 (en) 2014-09-22 2017-04-13 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
EP3268470B1 (fr) 2015-03-11 2020-11-18 Board of Regents, The University of Texas System Polypeptides de transposase et leurs utilisations
EP3138579A1 (fr) * 2015-09-05 2017-03-08 Biomay Ag Protéine de fusion pour son utilisation dans le traitement d'une infection par le virus de l'hépatite b
SG11201802912PA (en) 2015-10-10 2018-05-30 Intrexon Corp Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
AU2016341919A1 (en) 2015-10-21 2018-04-19 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating hepatitis b virus
CA3004742A1 (fr) 2015-11-11 2017-05-18 Intrexon Corporation Compositions et procedes d'expression de multiples polypeptides biologiquement actifs a partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
KR20200130339A (ko) 2018-03-06 2020-11-18 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
CA3092935A1 (fr) 2018-03-06 2019-09-12 Precigen, Inc. Vaccins contre l'hepatite b et utilisations de ces derniers

Also Published As

Publication number Publication date
US20230279057A1 (en) 2023-09-07
JP2024043538A (ja) 2024-03-29
US11608362B2 (en) 2023-03-21
EP3762010A4 (fr) 2022-04-06
CA3092935A1 (fr) 2019-09-12
AU2019231652A1 (en) 2020-10-01
KR20200128703A (ko) 2020-11-16
ZA202005672B (en) 2024-01-31
EP3762010A1 (fr) 2021-01-13
US20210015911A1 (en) 2021-01-21
CN112135622A (zh) 2020-12-25
WO2019173463A1 (fr) 2019-09-12
JP2021514666A (ja) 2021-06-17
IL277128A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
IL271025A (en) Multibiotic substances and methods of using them
IL276515A (en) Antibodies specific to PD-L1 and methods of using them
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
IL275427A (en) Hepatitis virus vaccines HBV) B) and their uses
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
IL283278A (en) Liver-specific viral promoters and methods of using the same
HK1244512A1 (zh) 突變型smoothened及其使用方法
ZA202004538B (en) Influenza virus vaccines and uses thereof
EP3419425A4 (fr) Dispositifs de cuisson et leurs procédés d'utilisation
IL277129A (en) Human papillomavirus vaccines and their uses
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
IL277128A (en) Hepatitis B vaccines and their uses
PL3463469T3 (pl) Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi
ZA202104244B (en) Recombinant viruses and the uses thereof
IL267450A (en) Antibodies against lif and their uses
IL280369A (en) Myokines and their uses
EP3897691A4 (fr) Vaccins contenant de l'il-10 et leurs utilisations
HK1259329A1 (zh) 包含乙型肝炎病毒的表面抗原和核衣殼抗原的藥用組合物
EP3473639A4 (fr) Inhibiteur du virus de l'hépatite c et application
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201808500D0 (en) Virus and virus use
PL3244921T3 (pl) Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV
PT3555132T (pt) Anticorpos contra lif e suas utilizações
GB201803401D0 (en) Polypeptide and vaccine
GB201803388D0 (en) Polypeptide and vaccine